Cellectar Biosciences‘ public offering raised $8 million, the company announced today. “We are pleased with the results of this offering, including the underwriter’s exercise of their full over-allotment option,” Cellectar…

Cellectar Biosciences announced today it is the recipient of a $2.3 million Fast-Track SBIR grant. According to a release, the money from the National Cancer Institute will help fund development of the…

Cellectar Biosciences today announced it is looking to raise $3.3 million through Wednesday by pricing common stock at $2.20 per share. According to a release, the company looks to use the…

Cellectar Biosciences CEO Jim Caruso was chosen to present at the Rodman & Renshaw 17th Annual Global Investment Conference, taking place Sept. 10 in New York City, the organization announced recently. “The…

Cellectar Biosciences named Jim Caruso to be its new President and CEO, the company announced today. “(Jim) brings a level of energy and commitment, combined with his significant industry experience that…

Cellectar Biosciences, which develops agents to detect, treat and monitor cancers, announced today it has initiated patient dosing in a proof-of-concept trial of I-131-CLR1404 in those with multiple melanoma. “I-131-CLR1404…

Cellectar Biosciences, which develops agents to detect, treat and monitor cancers, announced today it has applied to the U.S. Food & Drug Administration to begin a clinical study of a highly-selective,…

Cellectar Biosciences announced Wednesday that Acting CEO Simon Pedder, PhD., has been promoted to president and CEO. Dr. Pedder began his new role on Tuesday. “I am … appreciative of…